Tirzepatide

Tirzepatide is a single engineered 39-amino-acid peptide, carrying a C20 fatty-diacid chain that extends its half-life, reported to act on two incretin receptor pathways at once, whereas classic incretin research peptides are characterised by activity at a single receptor. This combined interaction profile is the main reason it is investigated separately in metabolic-signalling research. NOX supplies it as a lyophilised research reference material for research use only.

It is reported to engage both the GIP and the GLP-1 receptor, the two incretin pathways linked to metabolic signalling. The literature often calls it an "imbalanced" agonist, with high potency at the GIP receptor and biased signalling at the GLP-1 receptor, and investigators study how simultaneous activity at both targets is characterised in vitro and in preclinical models. This is educational context only; the compound is supplied for research use only.

Tirzepatide is most often referenced in metabolic and energy-balance research, where investigators examine incretin-receptor signalling and downstream pathways in laboratory and preclinical settings. It is not associated with any medical, therapeutic or human-use application. As with every NOX compound, it is a research reference material for research use only.

Lyophilised Tirzepatide is supplied as a sealed, freeze-dried powder and is generally kept frozen and away from light, typically stored at around -20°C for long-term stability, while for shorter periods it can be kept in the fridge at 2–8°C. Keeping the vial sealed limits moisture uptake and helps preserve the dry material. This describes general laboratory handling of lyophilised research compounds and is provided for research use only, not as guidance for any other use.

Bacteriostatic water is commonly used to reconstitute lyophilised research compounds because the small amount of benzyl alcohol it contains helps limit microbial growth in a multi-use vial. It simply dissolves the freeze-dried powder into a liquid so the material can be handled in the laboratory. Reconstitution is performed strictly within a research context; Tirzepatide is supplied by NOX for research use only.

Once reconstituted, Tirzepatide is in solution and generally less stable than the dry powder, so the liquid is typically kept in the fridge at 2–8°C and protected from light. Researchers usually prepare only what a study requires and record the reconstitution date. This reflects general laboratory handling of reconstituted research materials and is offered for research-use-only context, not as guidance for human or veterinary use.

Tirzepatide is supplied as a lyophilised powder in 20 mg. The stated strength is the mass of compound sealed in the vial before reconstitution; the working concentration depends on the volume of solvent a researcher adds during preparation. All presentations are research reference materials supplied for research use only.

Yes. Tirzepatide is supplied by NOX strictly as a research reference material for laboratory and analytical use. It is not a medicinal product, food, cosmetic or veterinary product, and nothing in these answers should be read as guidance for human or animal use. All information here is provided for educational and research context only.